Astex Pharmaceuticals (SUPG) Inactive 10-Q2007 Q1 Quarterly report

Filed: 10 May 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	8th grade Good

New words: anniversary, anticancer, Celgene, complement, department, forward, fourth, France, GAAP, GCP, grow, hedge, home, Hospira, inappropriately, India, knowledge, merger, mitigate, practice, Revlimid, Spain, training, unrestricted

Removed: abbott, abbreviated, absence, acquiring, adenocarcinoma, administered, advancement, Agency, agent, allocated, amortizing, anticipation, APB, approvable, attached, attention, attributable, Avicine, batch, begin, behavior, blood, budget, busulfan, buying, calculation, California, care, charged, chemical, chemotherapeutic, chemotherapy, collection, combined, combining, Commissioner, committed, computing, continually, core, cyclodextrin, cytotoxic, dating, decreased, dedicate, designed, destroy, dialog, direct, disrupt, disseminated, distributor, diversion, enrolled, estimating, excipient, excluded, exclusively, exempt, expanded, extended, extension, extensive, failed, feedback, focusing, gemcitabine, group, half, hematological, hold, Hungary, identifying, inadvertently, inert, initially, input, integrate, integration, internally, intravenously, investigational, investor, leading, leak, lesser, Letter, maintained, managed, materialize, mechanism, median, minimizing, missed, Mitozytrex, mix, NDA, objective, order, owner, palliative, pancreatic, Partaject, Peregrine, physician, planning, plastic, population, preclinical, present, primary, proceed, promote, proposed, prospectively, protocol, proven, quoted, randomized, realize, registration, regularly, requested, restructuring, resubmission, retained, security, served, shield, short, site, solid, solubility, specifically, spent, stability, stated, stomach, stopped, strong, subsequently, supported, surgery, target, technical, therapy, threshold, tissue, traded, transfusion, tumor, ulceration, ultimate, unamortized, undergone, understated, unpledged, utilizing, vaccine, Vascular, VEGF, vein, wound, Zealand

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SUPG similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, James S.J. Manuso, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of SuperGen, Inc. on Form 10-Q for the quarterly period ended March 31, 2007 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects the financial condition and results of operations of SuperGen, Inc.

	By:	/s/ JAMES S.J. MANUSO
	Name:	James S.J. Manuso
	Title:	President and Chief Executive Officer
		(Principal Executive Officer)

I, Michael Molkentin, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of SuperGen, Inc. on Form 10-Q for the quarterly period ended March 31, 2007 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects the financial condition and results of operations of SuperGen, Inc.

	By:	/s/ MICHAEL MOLKENTIN
	Name:	Michael Molkentin
	Title:	Chief Financial Officer
		(Principal Financial and Accounting Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.